638 related articles for article (PubMed ID: 22561106)
1. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting.
Fazil M; Md S; Haque S; Kumar M; Baboota S; Sahni JK; Ali J
Eur J Pharm Sci; 2012 Aug; 47(1):6-15. PubMed ID: 22561106
[TBL] [Abstract][Full Text] [Related]
2. Preparation of estradiol chitosan nanoparticles for improving nasal absorption and brain targeting.
Wang X; Chi N; Tang X
Eur J Pharm Biopharm; 2008 Nov; 70(3):735-40. PubMed ID: 18684400
[TBL] [Abstract][Full Text] [Related]
3. Complexation as an approach to entrap cationic drugs into cationic nanoparticles administered intranasally for Alzheimer's disease management: preparation and detection in rat brain.
Hanafy AS; Farid RM; ElGamal SS
Drug Dev Ind Pharm; 2015; 41(12):2055-68. PubMed ID: 26133084
[TBL] [Abstract][Full Text] [Related]
4. Venlafaxine loaded chitosan NPs for brain targeting: pharmacokinetic and pharmacodynamic evaluation.
Haque S; Md S; Fazil M; Kumar M; Sahni JK; Ali J; Baboota S
Carbohydr Polym; 2012 Jun; 89(1):72-9. PubMed ID: 24750606
[TBL] [Abstract][Full Text] [Related]
5. Alginate coated chitosan core shell nanoparticles for oral delivery of enoxaparin: in vitro and in vivo assessment.
Bagre AP; Jain K; Jain NK
Int J Pharm; 2013 Nov; 456(1):31-40. PubMed ID: 23994363
[TBL] [Abstract][Full Text] [Related]
6. Quantification and Brain Targeting of Eugenol-Loaded Surface Modified Nanoparticles Through Intranasal Route in the Treatment of Cerebral Ischemia.
Ahmad N; Ahmad R; Alam MA; Ahmad FJ
Drug Res (Stuttg); 2018 Oct; 68(10):584-595. PubMed ID: 29669380
[TBL] [Abstract][Full Text] [Related]
7. Thiolated chitosan nanoparticles for the nasal administration of leuprolide: bioavailability and pharmacokinetic characterization.
Shahnaz G; Vetter A; Barthelmes J; Rahmat D; Laffleur F; Iqbal J; Perera G; Schlocker W; Dünnhaput S; Augustijns P; Bernkop-Schnürch A
Int J Pharm; 2012 May; 428(1-2):164-70. PubMed ID: 22421322
[TBL] [Abstract][Full Text] [Related]
8. Bromocriptine loaded chitosan nanoparticles intended for direct nose to brain delivery: pharmacodynamic, pharmacokinetic and scintigraphy study in mice model.
Md S; Khan RA; Mustafa G; Chuttani K; Baboota S; Sahni JK; Ali J
Eur J Pharm Sci; 2013 Feb; 48(3):393-405. PubMed ID: 23266466
[TBL] [Abstract][Full Text] [Related]
9. Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies.
Joshi SA; Chavhan SS; Sawant KK
Eur J Pharm Biopharm; 2010 Oct; 76(2):189-99. PubMed ID: 20637869
[TBL] [Abstract][Full Text] [Related]
10. [Preparation of rivastigmine liposome and its pharmacokinetics in rats after intranasal administration].
Yang ZZ; Wang ZZ; Wu K; Qi XR
Yao Xue Xue Bao; 2011 Jul; 46(7):859-63. PubMed ID: 22010358
[TBL] [Abstract][Full Text] [Related]
11. Brain targeted nanoparticulate drug delivery system of rasagiline via intranasal route.
Mittal D; Md S; Hasan Q; Fazil M; Ali A; Baboota S; Ali J
Drug Deliv; 2016; 23(1):130-9. PubMed ID: 24786489
[TBL] [Abstract][Full Text] [Related]
12. Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery.
Rukmangathen R; Yallamalli IM; Yalavarthi PR
Drug Dev Ind Pharm; 2019 Aug; 45(8):1342-1350. PubMed ID: 31094571
[No Abstract] [Full Text] [Related]
13. Preparation and evaluation of N-caproyl chitosan nanoparticles surface modified with glycyrrhizin for hepatocyte targeting.
Lin A; Chen J; Liu Y; Deng S; Wu Z; Huang Y; Ping Q
Drug Dev Ind Pharm; 2009 Nov; 35(11):1348-55. PubMed ID: 19832635
[TBL] [Abstract][Full Text] [Related]
14. Formulation, development and optimization of raloxifene-loaded chitosan nanoparticles for treatment of osteoporosis.
Saini D; Fazil M; Ali MM; Baboota S; Ali J
Drug Deliv; 2015; 22(6):823-36. PubMed ID: 24725026
[TBL] [Abstract][Full Text] [Related]
15. Glycyrrhizin surface-modified chitosan nanoparticles for hepatocyte-targeted delivery.
Lin A; Liu Y; Huang Y; Sun J; Wu Z; Zhang X; Ping Q
Int J Pharm; 2008 Jul; 359(1-2):247-53. PubMed ID: 18457928
[TBL] [Abstract][Full Text] [Related]
16. Design and evaluation of novel pH-sensitive chitosan nanoparticles for oral insulin delivery.
Makhlof A; Tozuka Y; Takeuchi H
Eur J Pharm Sci; 2011 Apr; 42(5):445-51. PubMed ID: 21182939
[TBL] [Abstract][Full Text] [Related]
17. Brain transport of neurotoxin-I with PLA nanoparticles through intranasal administration in rats: a microdialysis study.
Cheng Q; Feng J; Chen J; Zhu X; Li F
Biopharm Drug Dispos; 2008 Nov; 29(8):431-9. PubMed ID: 18837064
[TBL] [Abstract][Full Text] [Related]
18. Brain delivery of buspirone hydrochloride chitosan nanoparticles for the treatment of general anxiety disorder.
Bari NK; Fazil M; Hassan MQ; Haider MR; Gaba B; Narang JK; Baboota S; Ali J
Int J Biol Macromol; 2015 Nov; 81():49-59. PubMed ID: 26210037
[TBL] [Abstract][Full Text] [Related]
19. Development, optimisation and evaluation of chitosan nanoparticles of alendronate against Alzheimer's disease in intracerebroventricular streptozotocin model for brain delivery.
Zameer S; Ali J; Vohora D; Najmi AK; Akhtar M
J Drug Target; 2021 Feb; 29(2):199-216. PubMed ID: 32876502
[TBL] [Abstract][Full Text] [Related]
20. Development and characterisation of chitosan films impregnated with insulin loaded PEG-b-PLA nanoparticles (NPs): a potential approach for buccal delivery of macromolecules.
Giovino C; Ayensu I; Tetteh J; Boateng JS
Int J Pharm; 2012 May; 428(1-2):143-51. PubMed ID: 22405987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
